INCYTE CORPORATION;MERCK SHARP AND DOHME CORPORATION
发明人:
Lance LEOPOLD,David KAUFMAN
申请号：
US16375405
公开号：
US20190270812A1
申请日:
2019.04.04
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1), and the use of the combination therapies for the treat-ment of cancer, and in particular for treating cancers that express PD-L 1.
